UBS Group’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.87M | Sell |
2,483,182
-524,055
| -17% | -$762K | ﹤0.01% | 4334 |
|
|
2025
Q4 | $3.46M | Buy |
3,007,237
+2,654,315
| +752% | +$3.65M | ﹤0.01% | 4395 |
|
|
2025
Q3 | $476K | Sell |
352,922
-47,810
| -12% | -$54.3K | ﹤0.01% | 6127 |
|
|
2025
Q2 | $379K | Sell |
400,732
-1,694,608
| -81% | -$1.1M | ﹤0.01% | 6242 |
|
|
2025
Q1 | $966K | Buy |
2,095,340
+1,409,223
| +205% | +$889K | ﹤0.01% | 5306 |
|
|
2024
Q4 | $507K | Buy |
686,117
+546,125
| +390% | +$658K | ﹤0.01% | 5827 |
|
|
2024
Q3 | $220K | Sell |
139,992
-21,121
| -13% | -$37.6K | ﹤0.01% | 5800 |
|
|
2024
Q2 | $271K | Sell |
161,113
-5,848
| -4% | -$10.5K | ﹤0.01% | 5450 |
|
|
2024
Q1 | $401K | Sell |
166,961
-2,655
| -2% | -$5.7K | ﹤0.01% | 5371 |
|
|
2023
Q4 | $260K | Buy |
169,616
+44,254
| +35% | +$52.6K | ﹤0.01% | 5606 |
|
|
2023
Q3 | $137K | Buy |
125,362
+27,799
| +28% | +$48.8K | ﹤0.01% | 5632 |
|
|
2023
Q2 | $223K | Sell |
97,563
-41,163
| -30% | -$109K | ﹤0.01% | 5404 |
|
|
2023
Q1 | $337K | Sell |
138,726
-21,092
| -13% | -$48.3K | ﹤0.01% | 4989 |
|
|
2022
Q4 | $305K | Buy |
159,818
+66,132
| +71% | +$141K | ﹤0.01% | 5108 |
|
|
2022
Q3 | $225K | Sell |
93,686
-118,467
| -56% | -$328K | ﹤0.01% | 4984 |
|
|
2022
Q2 | $395K | Buy |
212,153
+87
| +0% | +$166 | ﹤0.01% | 4426 |
|
|
2022
Q1 | $443K | Buy |
212,066
+116,066
| +121% | +$322K | ﹤0.01% | 4777 |
|
|
2021
Q4 | $378K | Buy |
96,000
+92,026
| +2,316% | +$447K | ﹤0.01% | 5202 |
|
|
2021
Q3 | $19K | Buy |
3,974
+1,983
| +100% | +$8.14K | ﹤0.01% | 7212 |
|
|
2021
Q2 | $9K | Sell |
1,991
-11,657
| -85% | -$56.1K | ﹤0.01% | 8145 |
|
|
2021
Q1 | $80K | Buy |
13,648
+1
| +0% | +$7 | ﹤0.01% | 6129 |
|
|
2020
Q4 | $46K | Buy |
13,647
+10,726
| +367% | +$20.5K | ﹤0.01% | 6265 |
|
|
2020
Q3 | $4K | Sell |
2,921
-23,970
| -89% | -$42.7K | ﹤0.01% | 7419 |
|
|
2020
Q2 | $54K | Buy |
26,891
+10,416
| +63% | +$20.4K | ﹤0.01% | 5790 |
|
|
2020
Q1 | $32K | Sell |
16,475
-31,973
| -66% | -$95.2K | ﹤0.01% | 6169 |
|
|
2019
Q4 | $201K | Buy |
48,448
+24,370
| +101% | +$93.8K | ﹤0.01% | 5603 |
|
|
2019
Q3 | $73K | Buy |
24,078
+16,463
| +216% | +$51K | ﹤0.01% | 5959 |
|
|
2019
Q2 | $48K | Buy |
7,615
+2,390
| +46% | +$14.3K | ﹤0.01% | 5964 |
|
|
2019
Q1 | $29K | Sell |
5,225
-172,661
| -97% | -$1.05M | ﹤0.01% | 5972 |
|
|
2018
Q4 | $1.18M | Buy |
177,886
+14,822
| +9% | +$120K | ﹤0.01% | 3516 |
|
|
2018
Q3 | $1.74M | Buy |
163,064
+40,405
| +33% | +$463K | ﹤0.01% | 3349 |
|
|
2018
Q2 | $1.47M | Sell |
122,659
-96,264
| -44% | -$985K | ﹤0.01% | 3439 |
|
|
2018
Q1 | $1.88M | Buy |
218,923
+106,392
| +95% | +$984K | ﹤0.01% | 3196 |
|
|
2017
Q4 | $1.11M | Sell |
112,531
-46,115
| -29% | -$479K | ﹤0.01% | 3699 |
|
|
2017
Q3 | $1.95M | Buy |
158,646
+25,330
| +19% | +$374K | ﹤0.01% | 3147 |
|
|
2017
Q2 | $2.19M | Buy |
133,316
+2,446
| +2% | +$37.9K | ﹤0.01% | 2932 |
|
|
2017
Q1 | $1.88M | Buy |
130,870
+11,183
| +9% | +$166K | ﹤0.01% | 3002 |
|
|
2016
Q4 | $1.66M | Buy |
119,687
+84,892
| +244% | +$1.36M | ﹤0.01% | 3087 |
|
|
2016
Q3 | $629K | Sell |
34,795
-21,151
| -38% | -$340K | ﹤0.01% | 3760 |
|
|
2016
Q2 | $802K | Buy |
55,946
+3,657
| +7% | +$49.6K | ﹤0.01% | 3560 |
|
|
2016
Q1 | $625K | Sell |
52,289
-91,323
| -64% | -$957K | ﹤0.01% | 3606 |
|
|
2015
Q4 | $1.91M | Buy |
143,612
+121,677
| +555% | +$1.5M | ﹤0.01% | 2835 |
|
|
2015
Q3 | $235K | Buy |
21,935
+6,503
| +42% | +$71K | ﹤0.01% | 4500 |
|
|
2015
Q2 | $125K | Buy |
15,432
+3,847
| +33% | +$28.3K | ﹤0.01% | 5231 |
|
|
2015
Q1 | $77K | Buy |
11,585
+4,448
| +62% | +$30.4K | ﹤0.01% | 5642 |
|
|
2014
Q4 | $46K | Buy |
+7,137
| New | +$57.5K | ﹤0.01% | 6587 |
|
Other funds holding LXRX
AG
SL
SC
VCM
